Dundee analyst: misinformed idiot
The likely reason for the decline today is yet another very misinformed and short sighted note by David Martin of Dundee.
He has reevaluated the 1402 results and come up with the conclusion that "the potency of 1402 is substantially less than epo "
He bases this on the fact that EPO was administered to patients BY INJECTION 3-4 times a week whereby 1402 was administered by PILL 3 times / day......
For this reason he concludes, " we believe our finding introduces risk to the development of the compound "
WHAT AN ABSOLUTE IDIOT this guys is....
FIRST OF ALL : the company has said over and over that this drug is ideally suited to be used WITH EPO where the EPO dose can be reduced and where the 1402 is additive administered orally.
Two things, the stimulative results (in vitro ) of combining the two drugs was almost DOUBLE the effect of EPO on its own...
Second, 1402 can be produced for a fraction the cost of EPO so the overall program can be LESS MONEY with BIGGER EFFICACY...
1402 has ZERO side effects...
EPO only works on 65% of patients... what about 1402 ?
Do you think companies like Amgen or J&J just might have an interest in this....!?
UHHH DAVE.... did you not consider that part or are you just talking up your firm or client's short positions ? or is it just that you have some kind of grudge ?
THIS GUY IS GOING TO LOOK VERY STUPID a month or two from now. I have no doubt that this news has gotten the attention of big pharma... no matter how you slice it this is a big deal.
what a total idiot... what a disgrace to the analyst community